BPC-157
Body Protection Compound
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. With over 100 published preclinical studies, it is among the most extensively researched cytoprotective peptides — studied across tissue repair, angiogenesis, gut integrity, tendon healing, and CNS models.
At a Glance
BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide sequence derived from a naturally occurring protein in gastric juice. Its cytoprotective properties were first characterized in the early 1990s and have since been studied across a remarkably broad range of tissue and organ systems in preclinical models.
What distinguishes BPC-157 in the research literature is the consistency of its effects across tissue types. Unlike compounds with narrow mechanism profiles, BPC-157 has demonstrated activity in tendon, ligament, muscle, bone, gut, liver, cornea, and CNS models — suggesting a fundamental cytoprotective mechanism that operates across tissue boundaries.
The April 2026 FDA reclassification removed BPC-157 from the Category 2 bulks list, simplifying the regulatory posture for research-only vendors. It remains a research chemical — not approved for human or veterinary use.
BPC-157 operates through several converging biological pathways, which helps explain the breadth of effects observed across different tissue and organ models.
Angiogenesis Promotion
Upregulates VEGF expression and promotes formation of new blood vessels at injury sites, accelerating the delivery of repair factors and oxygen to damaged tissue.
Growth Factor Modulation
Interacts with the growth hormone receptor and modulates expression of multiple growth factors including EGF, FGF, and PDGF — key mediators of tissue repair signaling.
Nitric Oxide Pathway
Modulates nitric oxide synthesis, influencing vascular tone and blood flow at injury sites. Both nNOS and eNOS pathways appear involved depending on tissue type.
Cytoprotection
Protects cells against oxidative stress, toxins, and ischemic damage. Particularly well-studied in gastric and intestinal epithelium, where it was originally characterized.
- Tendon and ligament repair — accelerated healing in Achilles tendon, MCL, and rotator cuff models
- Gut integrity and IBD models — mucosal protection, fistula healing, colitis attenuation
- Muscle injury recovery — myosin heavy chain repair, crush injury models
- Bone healing — fracture repair acceleration in rodent models
- CNS neuroprotection — traumatic brain injury, spinal cord injury, dopamine system modulation
- Angiogenesis research — VEGF upregulation, wound vascularization
- Liver protection — alcohol-induced damage, NSAID hepatotoxicity models
- Corneal healing — chemical burn and mechanical injury models
BPC-157 is most commonly compared to TB-500 and GHK-Cu in tissue repair research contexts. Each operates through distinct mechanisms.
| Aspect | BPC-157 | TB-500 | GHK-Cu |
|---|---|---|---|
| Primary Mechanism | Cytoprotection, angiogenesis | Actin regulation, cell migration | Collagen synthesis, gene expression |
| Activity Pattern | Localized to injury site | Systemic cell mobilization | Matrix remodeling |
| Gut Research | Extensive — primary origin | Limited | Limited |
| CNS Data | Substantial | Limited | Moderate |
| Study Count | 100+ | 40+ | 50+ |
Extensive preclinical safety data — 100+ studies across multiple species with no significant toxicity signals
No LD50 established — no lethal dose found in rodent studies even at very high doses
Stable compound — lyophilized powder stable at room temperature short-term; -20°C for long-term storage
No human clinical trials — all safety data from preclinical models; human pharmacokinetics unknown
This overview is strictly educational and based on publicly available scientific literature as of 2026. It does not constitute medical advice. All Helixera Labs products are for laboratory research use only. Not for human or veterinary use. · Helixera Labs LLC © 2026